Janux Therapeutics, Inc. (JANX) Misses Q3 EPS by 18c

Janux Therapeutics, Inc. (NASDAQ: JANX) reported Q3 EPS of ($0.51), $0.18 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $440 thousand versus the consensus estimate of $755 thousand.

For earnings history and earnings-related data on Janux Therapeutics, Inc. (JANX) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• 22nd Century Group files prospectus for warrant share resale
• Ticketplus files for IPO with shares priced between $13-$15